GE HealthCare announces five new global collaborations to advance the next generation of theranostics imaging
Leading institutions will evaluate StarGuide GXi across quantitative imaging, dynamic imaging and emerging theranostic applications
Clinical experience from more than 1,000 patient studies was established ahead of the European Association of Nuclear Medicine (EANM) 2026 Annual Meeting in Vienna, Austria
Insights will help guide the future evolution of GE HealthCare's digital SPECT/CT platform and inform the next generation of nuclear medicine imaging
CHICAGO & VIENNA, October 20, 2026--GE HealthCare (Nasdaq: GEHC) today announced a global clinical evaluation program spanning three continents and five internationally recognized institutions to assess StarGuide™ GX,i its next-generation digital 4D SPECT/CT system. Participating institutions include Hadassah Medical Center in Israel; Mayo Clinic in the United States; Oncopole Claudius Regaud – Institut Universitaire du Cancer de Toulouse in France; Peking University First Hospital in China; and Rambam Health Care Campus.
Across the program, participating institutions will evaluate image quality, quantitative performance, dynamic imaging and workflow while providing clinical and research feedback to help inform the future evolution of StarGuide GX.
"Nuclear medicine is entering a new era in which imaging is expected to do more than identify disease – it is increasingly being used to quantify biological processes, support treatment decisions and monitor response to therapy," said Erez Levy, Executive Director, Molecular Imaging, GE HealthCare. "By working across multiple regions and care environments, we aim to generate clinical and research insights that can help inform innovation as imaging, quantitation and workflow needs evolve."
Expanding quantitative and dynamic imaging capabilities
StarGuide GX uses dual-sided cadmium zinc telluride (dsCZT) detector technology and is designed to support high-sensitivity, high-resolution imaging, quantitative imaging and dynamic acquisitions. Its detector configuration allows the detectors to move close to the patient during imaging, while its patented dual-collimator detector design is intended to eliminate the need for manual external collimator exchanges and streamline imaging workflows.
Additionally, the system is engineered to support radionuclides across a broad energy range and, in research settings, it may also be evaluated for imaging radionuclides associated with emerging alpha-emitter research, including Actinium-225, focused on the potential to expand theranostic applications.ii